| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US11633374 | AZURITY | Compositions and methods for treating epilepsy, seizures and other conditions |
Aug, 2040
(16 years from now) | |
| US11433046 | AZURITY | Compositions and methods for treating epilepsy, seizures and other conditions |
Aug, 2040
(16 years from now) | |
Eprontia is owned by Azurity.
Eprontia contains Topiramate.
Eprontia has a total of 2 drug patents out of which 0 drug patents have expired.
Eprontia was authorised for market use on 05 November, 2021.
Eprontia is available in solution;oral dosage forms.
Eprontia can be used as indicated as adjunctive therapy for the treatment of partial-onset seizures, primary generalized tonic-clonic seizures, and seizures associated with lennox-gastaut syndrome in patients 2 years of age and older; indicated as initial monotherapy for the treatment of partial-onset or primary generalized tonic-clonic seizures in patients 2 years of age and older; indicated for the preventive treatment of migraine in patients 12 years and older.
The generics of Eprontia are possible to be released after 21 August, 2040.
Drugs and Companies using TOPIRAMATE ingredient
Market Authorisation Date: 05 November, 2021
Treatment: Indicated as adjunctive therapy for the treatment of partial-onset seizures, primary generalized tonic-clonic seizures, and seizures associated with lennox-gastaut syndrome in patients 2 years of age ...
Dosage: SOLUTION;ORAL
EPRONTIA family patents
900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight
Join them to stay ahead in capturing the next drug going generic